PT - JOURNAL ARTICLE AU - Jocelyn Chan AU - Heather F Gidding AU - Christopher C Blyth AU - Parveen Fathima AU - Sanjay Jayasinghe AU - Peter B McIntyre AU - Hannah C Moore AU - Kim Mulholland AU - Cattram D Nguyen AU - Ross Andrews AU - Fiona M Russell TI - Pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: a retrospective record linkage cohort study AID - 10.1101/2021.06.29.21259668 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.29.21259668 4099 - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259668.short 4100 - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259668.full AB - Background There is limited empiric evidence on the coverage of pneumococcal conjugate vaccines (PCV) required to generate substantial indirect protection. We investigate the association between population PCV coverage and indirect protection against invasive pneumococcal disease (IPD) and pneumonia hospitalisations among under-vaccinated Australian children.Methods Birth and vaccination records, IPD notifications and hospitalisations were individually linked for children aged < five years, born between 2001 and 2012 in two Australian states (New South Wales and Western Australia; 1.37 million children). Using Poisson regression models, we examined the association between PCV coverage, in small geographical units, and the incidence of (1) 7-valent PCV (PCV7)-type IPD, (2) all-cause pneumonia and (3) pneumococcal and lobar pneumonia hospitalisation in under-vaccinated children. Under-vaccinated children received < two doses of PCV at < 12 months of age and no doses at ≥ 12 months of age. Potential confounding variables were selected for adjustment a priori with the assistance of a directed acyclic graph. The main limitations of this study include the potential for differential loss to follow-up, geographical misclassification of children (based on addressed at birth only) and unmeasured confounders.Findings There were strong inverse associations between PCV coverage and the incidence of PCV7-type IPD (adjusted incidence rate ratio [aIRR] 0.967, 95% CI 0.958-0.975, p-value <0.001), and pneumonia hospitalisations (all-cause pneumonia: aIRR 0.991 95% CI 0.990-0.994, p-value<0.001) among under-vaccinated children. Subgroup analyses for children < four months old, urban, rural and Indigenous populations showed similar trends, although effects were smaller for rural and Indigenous populations. Fifty-percent coverage of PCV7 among children < five years of age prevented up to 72.5% (95% CI 51.6-84.4) of PCV7-type IPD among under-vaccinated children, while 90% coverage prevented 95.2% (95% CI 89.4-97.8).Conclusions In this study we observed substantial indirect protection at low PCV coverage, challenging assumptions high vaccine coverage is required.Why was this study done?Pneumococcal conjugate vaccines (PCVs) reduce the burden of pneumococcal disease in vaccinated and unvaccinated populations through both direct and indirect (herd) effects.The indirect effects comprise a substantial component of overall vaccine impact, contributing to the cost-effectiveness of the vaccine but little is known about what factors contribute to herd protection, including vaccination coverage.In this study, we examined association between PCV coverage and indirect effects within in diverse populations within AustraliaWhat did the researchers do and find?Using a large dataset of 1.3 million children from two states in Australia, we quantified the relationship between PCV coverage within small geographical units and indirect protection against pneumococcal disease. We also performed similar analyses for infants too young to be fully vaccinated, urban, rural and Indigenous populations.There were strong inverse relationships between PCV coverage and the incidence of severe invasive disease due to vaccine types and pneumonia hospitalisations among under-vaccinated children i.e. higher coverage were associated with greater reductions in disease due to indirect effects. We also found substantial indirect effects at relatively low levels of PCV coverage. We estimated that 50% and 90% coverage of 7-valent PCV (PCV7) among children under five years of age prevented almost three-quarters (72.5%, 95% CI 51.6-84.4) and almost all (95.2%, 95% CI 89.4-97.8) of PCV7-type severe invasive disease, respectively. For pneumonia, we estimated that 50% and 90% coverage was sufficient to prevent one-third (33.3%, 95% CI 27.3-38.8) and about half (51.7%, 95% CI 43.7-58.6) of all-cause pneumonia hospitalisations among under-vaccinated children.These trends were similar for children less than four months old, urban, rural and Indigenous populations, although these effects were smaller for rural and Indigenous populations. There was also a trend towards decreasing incidence of PCV13-type IPD among under-vaccinated children as PCV13 coverage increased.What do these findings mean?Our results challenge existing assumptions that high PCV coverage is required to achieve substantial indirect protection.Understanding the determinants of indirect effects are particularly urgent as countries that have controlled vaccine-type pneumococcal disease consider using reducing the number of PCV doses (from three to two). Reduced dose schedules have the potential to significantly lower program costs while maintaining vaccine impact, providing indirect protection is achieved and preserved.Competing Interest StatementKM is a member of the WHO SAGE Working Group on Pneumococcal Vaccines. CDN is an investigator on a study outside the submitted work that received funding from Pfizer inc. The other authors have declared that no competing interests exist.Funding StatementThis study was funded by the Population Health Research Network Proof of Concept Project, a capability of the Commonwealth Government Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative, and the Australian National Health and Medical Research Council (project grant GNT1082342, chief investigator HFG). HFG, CCB, HCM and FMR are funded by Australian National Health and Medical Research Council (NHMRC) fellowships. Specifically, FMR is funded by an NHMRC Translating Research into Practice (TRIP) fellowship and Investigator grant. JC is funded by the Australian Research Training Program scholarship. HCM is further supported by a Telethon Kids Institute Emerging Research Leader Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from: The Aboriginal Health and Medical Research Council Ethics Committee (approval ID: 931/13), AIHW Ethics Committee (approval ID: EC 2012/4/62), Department of Health Human Research Ethics Committee (approval ID: 1/2013), Department of Health - WA Human Research Ethics Committee (approval ID: 2012/75), NSW Population and Health Service Research Ethics Commit- tee (approval ID: HREC/13/CIPHS/15), and Western Australian Aboriginal Health Ethics Committee (approval ID: 459).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe custodians of the data used for this analysis are the New South Wales Centre for Health Record Linkage (https://www.cherel.org.au/) and Western Australia - Data Linkage (https://www.datalinkage-wa.org.au/). Interested researchers may apply at these sites for data access.